NextCell Pharma publishes its Interim Report 2 2024/2025

April 25, 2025

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period December 1, 2024 – February 28, 2025. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

 

Second Quarter (2024-12-01 to 2025-02-28)

  • Operating income amounted to 3,417 (2,405) TSEK, of which Cellaviva contributed 3,248 (2,334) TSEK.
  • Net sales amounted to 3,248 (2,334) TSEK.
  • Profit/loss after financial items amounted to -8,198 (-10,093) TSEK.
  • Earnings per share* were -0.11 (-0.29) SEK.
  • Cash and cash equivalents amounted to 26,338 (30,393) TSEK.
  • Equity ratio** amounted to 83 (79) percent.

First Half Year (2024-09-01 to 2025-02-28)

  • Operating income amounted to 6,281 (7,099) TSEK, of which Cellaviva contributed 6,077 (6,580) TSEK.
  • Net sales amounted to 6,077 (6,580) TSEK.
  • Profit/loss after financial items amounted to -16,240 (-19,889) TSEK.
  • Earnings per share* were -0.40 (-0.58) SEK.

*Earnings per share: Net result for the period divided by the average number of shares. The average number of shares for the second quarter of 2024/2025: 73,091,327 (34,379,523) shares. The average number of shares for the first half year of 2024/2025: 73,091,327 (34,379,523) shares. The number of shares in NextCell as of 28 February 2024: 73,091,327 (34,379,523) shares.
**Equity ratio: Shareholders’ equity as a percentage of total assets.

Significant events and news during the second quarter

  • In December, NextCell reported new results from the ProTrans-Repeat study. "The results from thePro­Trans-Repeat study are very encouraging and show that repeated treatment can preserve and even improve insulin production over six years. This strengthens ProTrans' potential as a safe and effective treatment for modifying the progression of type 1 diabetes," com­ment- ed Mathias Svahn, CEO.
     
  • Mid Februari NextCell announced that all patients in the clinical trial ProTrans V, where ProTrans is used for the treatment of severe virus-induced pneumonia, had been treated.

Significant events after the reporting period

  • At the end of March NextCell Pharma announced that the company's Chief Scientific Officer (CSO), Dr Lindsay Davies had been elected to the board of ATMP Sweden.
     
  • In the beginning of April NextCell Pharma announced preliminary one-year results from the older age group (12–21 years) in the ongoing clinical trial ProTrans-Young. The study is evaluating the safety and efficacy of the company’s cell therapy, ProTrans, in preserving insulin production in young individuals newly diagnosed with type 1 diabetes, compared with placebo.
     
  • NextCell Pharma announced early April that Dr Lindsay Davies, Chief Scientific Officer at NextCell Pharma AB, had been elected Vice President Elect for Europe within the International Society for Cell and Gene Therapy (ISCT).
     
  • Mid April NextCell Pharma published an interview where the analyst Filip Einarsson from Redeye, who currently covering NextCell, discussed with Mathias Svahn ques­tions regarding the latest results from ProTrans-YOUNG.

This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 25-04-2025 07:30 CET.

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com

Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma


For more information about Cellaviva, please contact
Sofie Falk Jansson, CEO Cellaviva AB
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se


Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva

Certified Adviser
RedEye AB is assigned as Certified Adviser.
The company's shares are listed on the Nasdaq First North Growth Market.

About NextCell Pharma AB
NextCell is a cell therapy company in Phase II trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase III trial. In addition to type 1 diabetes. NextCell owns Cellaviva AB, Scandinavia’s largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use. NextCell also owns QVance which will offer quality control analytics for advanced therapy developers. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology.

Download attachmentRead full press release on Cision (external link)
2026-10-26
NextCell reports encouraging numerical results in younger children – strategy for adults remains unchanged
NextCell Pharma AB (publ) (“NextCell” or the “Company”) today announces the 12-month results from ProTrans-Young. In the predefined age group of 7–11 years, children treated with NXTCL-T1D had, on average, preserved a greater proportion of their endogenous insulin production after 12 months and experienced a smaller increase in insulin requirements compared with those receiving placebo. The study did not meet its primary efficacy endpoint in the overall study population. A preliminary analysis of 24-month data from the older age group shows no clear treatment effect, although the data have not yet been fully analysed or validated. NextCell’s commercialisation strategy for adults remains unchanged, while the Company intends to refine its treatment strategy for children and adolescents, focusing on treatment timing and the number of administrations. Further analyses are also planned to investigate how age and individual disease progression may influence treatment response.
Read moreRead more
2026-10-19
NextCell provides update on timing of ProTrans-Young results
NextCell Pharma AB (publ) (“NextCell” or the “Company”) announces that topline results from the ProTrans-Young clinical trial have not yet been reported to the company. The extended timeline is due to the final administrative processing and sign-off of study data taking longer than planned and is not related to the outcome of the study. The data are now being handled by statisticians at Uppsala Clinical Research Center (UCR).
Read moreRead more
2026-09-28
NextCell to present at the INNODIA Symposium during EASD 2026
NextCell Pharma AB (publ) (“NextCell” or the “Company”) has been invited to present its clinical development programme in type 1 diabetes at the INNODIA Symposium on T1D Therapies, held in connection with the European Association for the Study of Diabetes (EASD) 2026 meeting in Milan on 28 September. The presentation will focus on NextCell’s clinical programme for NXTCL-T1D, including long-term data from adult patients showing preservation of endogenous insulin production for more than six years following a single infusion.
Read moreRead more
2026-08-27
Interim Report second quarter 2026
NextCell Pharma AB (publ) (“NextCell” or the “Company”) publishes its Interim report for the second quarter 2026. The report is available on the company´s website: www.nextcellpharma.com. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period last year.  Please note that, as of 2025, the Company’s financial year corresponds to the calendar year.
Read moreRead more
2026-08-18
NextCell Selected for EU-Japan Biotech Business Mission and Strengthens Presence in Hong Kong
NextCell Pharma AB ("NextCell" or the "Company") has been selected as the only Swedish company to participate in the EU-Japan Biotech Business Mission 2026. In parallel, the Company is strengthening its local presence in Hong Kong by establishing an office and becoming a member of the Hong Kong-Shenzhen Innovation and Technology Park (HSITP), effective 1 September. NextCell will also participate as a Founding Partner in the Nordic Future Health Pavilion at BIOHK 2026, held 9–12 September.
Read moreRead more
2026-05-28
Interim Report first quarter 2026
NextCell Pharma AB (publ) (“NextCell” or the “Company”) publishes its Interim report for the first quarter 2026. The report is available on the company´s website: www.nextcellpharma.com. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period last year.  Please note that, as of 2025, the Company’s financial year corresponds to the calendar year.
Read moreRead more
2026-05-27
NextCell Pharma AB (publ) Annual General Meeting 2026
On Wednesday, 27 May 2026, the Annual General Meeting of NextCell Pharma AB (publ), reg. no. 556965-8361 (“NextCell” or the “Company”), was held. A summary of the resolutions adopted at the Annual General Meeting is set out below. All resolutions were adopted with the required majority. For more detailed information regarding the content of the resolutions, reference is made to the notice convening the Annual General Meeting and the complete proposals for resolutions, which have previously been published and are available on the Company’s website, www.nextcellpharma.com.
Read moreRead more
2026-05-06
NextCell and FUJIFILM Biosciences Launch New Commercial Platform Comprised of RUO Stromal Cells and Cell Culture Media
NextCell Pharma AB ("NextCell" or "the Company") today announces that in collaboration with FUJIFILM Biosciences, NextCell-Cord RUO cells have been commercially launched.
Read moreRead more